Importantly, administration of a CD39 inhibitor plus TIM3 blocking antibodies reduced tumor size and increased survival in a melanoma mouse model13, suggesting that blockade of pathways different from PD-1 may be beneficial, in particular in tumors rich in terminally exhausted CD8 cells27. Here, CD8A is linked to melanoma.